Scopus Biopharma Stock Performance
| SCPS Stock | USD 0.0006 0.0002 50.00% |
Scopus Biopharma holds a performance score of 8 on a scale of zero to a hundred. The entity has a beta of -0.16, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Scopus Biopharma are expected to decrease at a much lower rate. During the bear market, Scopus Biopharma is likely to outperform the market. Use Scopus Biopharma total risk alpha, daily balance of power, as well as the relationship between the Daily Balance Of Power and relative strength index , to analyze future returns on Scopus Biopharma.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Scopus Biopharma are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Scopus Biopharma unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.8 M | |
| Total Cashflows From Investing Activities | -1999.00 |
Scopus |
Scopus Biopharma Relative Risk vs. Return Landscape
If you would invest 0.04 in Scopus Biopharma on November 1, 2025 and sell it today you would earn a total of 0.02 from holding Scopus Biopharma or generate 50.0% return on investment over 90 days. Scopus Biopharma is currently generating 1.5574% in daily expected returns and assumes 13.9704% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Scopus, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Scopus Biopharma Target Price Odds to finish over Current Price
The tendency of Scopus OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0006 | 90 days | 0.0006 | roughly 2.15 |
Based on a normal probability distribution, the odds of Scopus Biopharma to move above the current price in 90 days from now is roughly 2.15 (This Scopus Biopharma probability density function shows the probability of Scopus OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Scopus Biopharma has a beta of -0.16. This usually implies as returns on the benchmark increase, returns on holding Scopus Biopharma are expected to decrease at a much lower rate. During a bear market, however, Scopus Biopharma is likely to outperform the market. In addition to that Scopus Biopharma has an alpha of 2.0689, implying that it can generate a 2.07 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Scopus Biopharma Price Density |
| Price |
Predictive Modules for Scopus Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Scopus Biopharma. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Scopus Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Scopus Biopharma is not an exception. The market had few large corrections towards the Scopus Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Scopus Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Scopus Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.07 | |
β | Beta against Dow Jones | -0.16 | |
σ | Overall volatility | 0.000083 | |
Ir | Information ratio | 0.13 |
Scopus Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Scopus Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Scopus Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Scopus Biopharma is way too risky over 90 days horizon | |
| Scopus Biopharma has some characteristics of a very speculative penny stock | |
| Scopus Biopharma appears to be risky and price may revert if volatility continues | |
| Scopus Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scopus Biopharma currently holds about 1.16 M in cash with (11.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 51.0% of Scopus Biopharma outstanding shares are owned by corporate insiders |
Scopus Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Scopus OTC Stock often depends not only on the future outlook of the current and potential Scopus Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Scopus Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13.4 M | |
| Cash And Short Term Investments | 7.9 M |
Scopus Biopharma Fundamentals Growth
Scopus OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Scopus Biopharma, and Scopus Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Scopus OTC Stock performance.
| Return On Equity | -15.6 | |||
| Return On Asset | -4.61 | |||
| Current Valuation | 1.18 M | |||
| Shares Outstanding | 21.09 M | |||
| Price To Book | 2.42 X | |||
| EBITDA | (26.18 M) | |||
| Cash And Equivalents | 1.16 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 2.54 M | |||
| Debt To Equity | 0.61 % | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (11.42 M) | |||
| Earnings Per Share | (1.51) X | |||
| Total Asset | 8.19 M | |||
About Scopus Biopharma Performance
Assessing Scopus Biopharma's fundamental ratios provides investors with valuable insights into Scopus Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Scopus Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. Scopus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Things to note about Scopus Biopharma performance evaluation
Checking the ongoing alerts about Scopus Biopharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Scopus Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Scopus Biopharma is way too risky over 90 days horizon | |
| Scopus Biopharma has some characteristics of a very speculative penny stock | |
| Scopus Biopharma appears to be risky and price may revert if volatility continues | |
| Scopus Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scopus Biopharma currently holds about 1.16 M in cash with (11.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 51.0% of Scopus Biopharma outstanding shares are owned by corporate insiders |
- Analyzing Scopus Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Scopus Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Scopus Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Scopus Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Scopus Biopharma's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Scopus Biopharma's otc stock. These opinions can provide insight into Scopus Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Scopus OTC Stock Analysis
When running Scopus Biopharma's price analysis, check to measure Scopus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scopus Biopharma is operating at the current time. Most of Scopus Biopharma's value examination focuses on studying past and present price action to predict the probability of Scopus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scopus Biopharma's price. Additionally, you may evaluate how the addition of Scopus Biopharma to your portfolios can decrease your overall portfolio volatility.